SAN DIEGO, Oct. 6, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Halozyme and argenx are expanding their existing global collaboration and license agreement that was signed in February 2019. Under the newly announced expansion, argenx gained the...